D. Aviezer

发表

Inhibition of vascular smooth muscle cell proliferation by a novel fibroblast growth factor receptor antagonist.

A. Yayon, A. Segev, D. Aviezer, 2002, Cardiovascular research.

Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis.

N. Galili, A. Yayon, A. Segev, 2000, Cancer research.

Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA

D. Noonan, R. Iozzo, A. Yayon, 1997, Molecular and cellular biology.

Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease.

Joel L Sussman, Israel Silman, J. Sussman, 2007, The Journal of biological chemistry.

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.

O. Dym, J. Sussman, I. Silman, 2007, Plant biotechnology journal.

Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF.

A. Yayon, D. Aviezer, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Heparin‐like inhibitory activity to fibroblast growth factor‐2 in wound fluids of patients with chronic skin ulcers and its modulation during wound healing

A. Yayon, D. Aviezer, M. David, 2001, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

Erratum: Properly oriented heparin-decasaccharide-induced dimers are the biologically active form of basic fibroblast growth factor (Biochemistry (April 22, 1997) 36:16 (4782-4791))

R. Powers, D. Kitchen, P. Bohlen, 1997 .

Properly oriented heparin-decasaccharide-induced dimers are the biologically active form of basic fibroblast growth factor.

R. Powers, D. Kitchen, F. Moy, 1997, Biochemistry.

Diminished heparin binding of a basic fibroblast growth factor mutant is associated with reduced receptor binding, mitogenesis, plasminogen activator induction, and in vitro angiogenesis.

A. Yayon, D. Aviezer, M. Safran, 1994, Biochemistry.

Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor.

A. Yayon, D. Aviezer, M. Safran, 1994, The Journal of biological chemistry.

Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease.

Yoram Tekoah, D. Aviezer, Yaniv Azulay, 2015, Molecular genetics and metabolism.

Identification of a neutralizing antibody determinant on basic fibroblast growth factor by screening a random phage‐epitope library

E. Katchalski‐Katzir, D. Givol, A. Yayon, 1995 .

Characteristics of Cartilage Biopsies Used for Autologous Chondrocytes Transplantation

D. Aviezer, D. Robinson, H. Ash, 2001, Cell transplantation.

Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems

Yoram Tekoah, D. Aviezer, M. Golembo, 2013, Bioscience reports.

Autologous chondrocyte transplantation for reconstruction of isolated joint defects: the Assaf Harofeh experience.

D. Aviezer, N. Halperin, D. Robinson, 2000, The Israel Medical Association journal : IMAJ.

Cyclodextrin-mediated crystallization of acid β-glucosidase in complex with amphiphilic bicyclic nojirimycin analogues.

J. Sussman, I. Silman, J. M. Benito, 2011, Organic & biomolecular chemistry.

6‐Amino‐6‐deoxy‐5,6‐di‐N‐(N′‐octyliminomethylidene)nojirimycin: Synthesis, Biological Evaluation, and Crystal Structure in Complex with Acid β‐Glucosidase

J. Sussman, I. Silman, C. Ortiz Mellet, 2009, Chembiochem : a European journal of chemical biology.

A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I Investigation

E. Galun, S. Hashmueli, D. Aviezer, 2009, PloS one.

disease taliglucerase alfa , a novel enzyme replacement therapy for Gaucher expressed recombinant glucocerebrosidase , − Pivotal trial with plant cell

Gheona Altarescu, Atul Mehta, Pilar Giraldo, 2012 .

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.

A. Mehta, S. Hashmueli, D. Aviezer, 2011, Blood.

9. Novel enzyme replacement therapy for Gaucher disease: Phase III pivotal clinical trial with plant cell expressed recombinantglucocerebrosidase (prGCD) – taliglucerase alpha

S. Hashmueli, D. Aviezer, A. Zimran, 2010 .

Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease.

C. Hollak, D. Aviezer, M. Maas, 2013, Blood cells, molecules & diseases.

Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease.

Yoram Tekoah, D. Aviezer, Y. Shaaltiel, 2015, Plant biotechnology journal.

Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia--genetic short limbed dwarfism.

A. Yayon, D. Aviezer, M. Golembo, 2003, Current drug targets.

Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis

A. Yayon, D. Aviezer, M. Safran, 1994, Cell.

6. Novel enzyme replacement therapy for Gaucher disease: On-going phase III clinical trial with recombinant human glucocerebrosidase expressed in plant cells

G. Galili, E. Galun, S. Hashmueli, 2008 .

Oligomerization reduces heparin affinity but enhances receptor binding of fibroblast growth factor 2.

M. Eisenstein, A. Yayon, D. Aviezer, 2000, The Biochemical journal.

Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library.

E. Katchalski‐Katzir, D. Givol, A. Yayon, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Glycosylation and functionality of recombinant glucocerebrosidase from various production systems

D. Aviezer, Y. Shaaltiel, Mariana Hainrichson, 2014 .

Mechanical Resistance of Biological Repair Cartilage: Comparative in vivo Tests of Different Surgical Repair Procedures

A. Yayon, T. Brosh, D. Aviezer, 2002, The International journal of artificial organs.

Development of a High Throughput Screening Assay for Inhibitors of Fibroblast Growth Factor-Receptor-Heparin Interactions

A. Yayon, M. Wildey, D. Aviezer, 2001, Journal of biomolecular screening.

Engineering of fibroblast growth factor: alteration of receptor binding specificity.

A. Yayon, D. Aviezer, P. Böhlen, 1995, Biochemistry.

Development of a High Throughput Screening Assay for Inhibitors of Fibroblast Growth Factor-Receptor-Heparin Interactions

A. Yayon, M. Wildey, D. Aviezer, 2001, Journal of biomolecular screening.

Heparin differentially regulates the interaction of fibroblast growth factor-4 with FGF receptors 1 and 2.

A. Yayon, D. Aviezer, M. Safran, 1999, Biochemical and biophysical research communications.

Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease.

Yoram Tekoah, D. Aviezer, Y. Shaaltiel, 2015, Plant biotechnology journal.

Crystal Structures of Complexes of N-Butyl- and N-Nonyl-Deoxynojirimycin Bound to Acid β-Glucosidase

J. Sussman, I. Silman, T. Butters, 2007, Journal of Biological Chemistry.